Publication Date:
1982-01-08
Description:
Subcutaneous injection of 50 micrograms of a luteinizing hormone-releasing factor agonist (LRF agonist) for three successive days at the time of menstruation in normal cycling women induces a shortened luteal phase with suboptimal concentrations of circulating estradiol and progesterone. This luteal phase defect follows a reduced concentration of follicle-stimulating hormone during the follicular phase and a resulting inadequate follicular maturation. Since a short luteal phase is associated with an endometrium not conductive to implantation, administration of the LRF agonist at the onset of menstrual cycle may prove to be a practical and novel approach to fertility control.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Sheehan, K L -- Casper, R F -- Yen, S S -- HD-12303/HD/NICHD NIH HHS/ -- N01HD-92842/HD/NICHD NIH HHS/ -- New York, N.Y. -- Science. 1982 Jan 8;215(4529):170-2.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/6797068" target="_blank"〉PubMed〈/a〉
Keywords:
Adult
;
*Contraception
;
Estradiol/blood
;
Female
;
Follicle Stimulating Hormone/blood/metabolism
;
Gonadotropin-Releasing Hormone/*analogs & derivatives/pharmacology
;
Humans
;
Luteinizing Hormone/blood
;
Menstruation/drug effects
;
Progesterone/blood
;
*Triptorelin Pamoate/*analogs & derivatives
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
